TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07908641: A Phase 1, Open-label, Crossover Study to Evaluate the Relative Bioavailability of Apremilast Extended-release and Immediate Release Formulations in Healthy Adult Participants.

Sponsor: Amgen · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 114 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,614,080

Rescue Site Savings

+$3,701,784

Unlock Full NCT07908641 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07908641 Rescue Dossier →